文献速递白血病造血干细胞移植与细胞治疗

诱导多能干细胞揭示幼年型粒单核细胞白血病突变特异性信号谱与激酶抑制剂敏感性

Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells.
PubMed 文献 · Leukemia · 2018-06-08

该研究利用患者来源的诱导多能干细胞(iPSCs)表征PTPN11突变与CBL突变幼年型粒单核细胞白血病(JMML)的信号谱与治疗脆弱性。在PTPN11或CBL突变的iPSC来源造血祖细胞中检测到Ras/MAPK与PI3K/mTOR通路组成性激活;PTPN11 iPSCs对MEK抑制剂PD0325901和曲美替尼的抑制更敏感,CBL iPSCs对JAK抑制剂莫美洛替尼和鲁索替尼的抑制更敏感,PI3Kδ抑制剂idelalisib与mTOR抑制剂雷帕霉素对两者均抑制信号与髓系增殖。作者认为可能值得在JMML儿童中开展突变特异性激酶抑制剂治疗的临床研究。

要点

  • PTPN11与CBL突变iPSC来源髓系细胞均存在Ras/MAPK与PI3K/mTOR信号组成性激活。
  • PTPN11 iPSCs的活化信号与生长优先被MEKi PD0325901和曲美替尼抑制。
  • CBL iPSCs的JAK/STAT信号选择性激活并被JAKi莫美洛替尼和鲁索替尼消除。

核心结论

  • PTPN11 iPSCs对MEKi、CBL iPSCs对JAKi表现出差异敏感性,但两者对PI3Ki和mTORi敏感性相似。
  • 作者认为可能值得在JMML儿童中开展突变特异性激酶抑制剂治疗的临床研究。

研究设计与样本

  • 利用患者来源的诱导多能干细胞(iPSCs)表征PTPN11突变与CBL突变JMML的信号谱与潜在治疗脆弱性。
  • 评估MEK、JAK和PI3K/mTOR激酶抑制剂能否抑制携带PTPN11 E76K或CBL Y371H突变的iPSC来源造血祖细胞的髓系增殖与异常信号。

主要发现

  • 在PTPN11与CBL iPSC来源髓系细胞中检测到组成性Ras/MAPK与PI3K/mTOR信号。
  • PTPN11 iPSCs的活化信号与生长在体外优先被MEKi PD0325901和曲美替尼抑制。
  • CBL iPSCs中JAK/STAT信号选择性激活,并被JAKi莫美洛替尼和鲁索替尼消除。
  • PI3Kδi idelalisib与mTORi雷帕霉素抑制PTPN11和CBL iPSCs两者的信号与髓系增殖。

临床怎么用

  • 作者认为可能值得在JMML儿童中开展突变特异性激酶抑制剂治疗的临床研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Juvenile myelomonocytic leukemia (JMML) is an uncommon myeloproliferative neoplasm driven by Ras pathway mutations and hyperactive Ras/MAPK signaling. Outcomes for many children with JMML remain dismal with current standard-of-care cytoreductive chemotherapy and hematopoietic stem cell transplantation. We used patient-derived induced pluripotent stem cells (iPSCs) to characterize the signaling profiles and potential therapeutic vulnerabilities of PTPN11-mutant and CBL-mutant JMML. We assessed whether MEK, JAK, and PI3K/mTOR kinase inhibitors (i) could inhibit myeloproliferation and aberrant signaling in iPSC-derived hematopoietic progenitors with PTPN11 E76K or CBL Y371H mutations. We detected constitutive Ras/MAPK and PI3K/mTOR signaling in PTPN11 and CBL iPSC-derived myeloid cells. Activated signaling and growth of PTPN11 iPSCs were preferentially inhibited in vitro by the MEKi PD0325901 and trametinib. Conversely, JAK/STAT signaling was selectively activated in CBL iPSCs and abrogated by the JAKi momelotinib and ruxolitinib. The PI3Kδi idelalisib and mTORi rapamycin inhibited signaling and myeloproliferation in both PTPN11 and CBL iPSCs. These findings demonstrate differential sensitivity of PTPN11 iPSCs to MEKi and of CBL iPSCs to JAKi, but similar sensitivity to PI3Ki and mTORi. Clinical investigation of mutation-specific kinase inhibitor therapies in children with JMML may be warranted.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Tasian SK, Casas JA, Posocco D, et al. Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells. Leukemia. 2018. PMID: 29884903. doi:10.1038/s41375-018-0169-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。